Drug Name: | Asparaginase (9015-68-3) |
---|---|
PubChem ID: | 124081179 |
SMILES: | C/C/1=C/2[C@@]([C@@H](C([N-]2)/C=C3/C([C@@H](/C(=C(/C4[C@]([C@H]([C@@H]([N-]4)[C@]5([C@@]([C@@H](C1[N-]5)CCC(=O)N)(C)CC(=O)N)C)CC(=O)N)(C)CCC(=O)NC[C@@H](C)O)C)/[N-]3)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N.[Co] |
InchiKey: | CPIBXUNAEPETCR-DEFJPDJUSA-N |
Therapeutic Category: | Antineoplastic Agents |
Molecular Weight (dalton) | : | 993.13 |
LogP | : | 3.4215 |
Ring Count | : | 0 |
Hydrogen Bond Acceptor Count | : | 8 |
Hydrogen Bond Donor Count | : | 8 |
Total Polar Surface Area | : | 364.27 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Bleeding | Histidine-rich glycoprotein (P04196) | L-Asparaginase therapy reduced plasma levels of plasminogen and histidine-rich glycoprotein ( HRG ) and influenced the equilibrium between HRG , plasminogen and HRG -plasminogen complex,which leads to the bleeding tendency [ ADR Type 1 ] | The influence of L-asparaginase therapy on the fibrinolytic system |
Deficiency Of Coagulation Factors | Alpha-2-antiplasmin (P08697) | Bleeding tendency described during L-asparaginase therapy can be ascribed not only to a temporary deficiency of coagulation factors but also to temporary alpha 2-antiplasmin deficiency [ ADR Type 3 ] | The influence of L-asparaginase therapy on the fibrinolytic system |
Deficiency Of Coagulation Factors | Coagulation factor (P00742) | Bleeding tendency described during L-asparaginase therapy can be ascribed not only to a temporary deficiency of coagulation factors but also to temporary alpha 2-antiplasmin deficiency. [ ADR Type 3 ] | The influence of L-asparaginase therapy on the fibrinolytic system |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category